Fortress Biotech Reports Record 2022 Financial Results and
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted...
Source: globenewswire.com
Jayd Kranzler News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jayd Kranzler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jayd Kranzler Today - Breaking & Trending Today
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
Fortress expects to file a total of three new drug applications in 2023 Record consolidated net revenue of $75.7 million for full-year 2022 FDA accepted for filing the Biologics License Application... | March 30, 2023
Source: marketscreener.com
Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
14.12.2022 - MIAMI, Dec. 14, 2022 (GLOBE NEWSWIRE) - Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and ... Seite 1
Source: wallstreet-online.de
2022-10-03 | NDAQ:FBIO | Press Release | Fortress Biotech Inc.
(2022-10-03 | NDAQ:FBIO) Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
Source: stockhouse.com
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace
Source: biospace.com